Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Segue o artigo citado pelo Prof. Dartiu Xavier da Silveira na Reunião Geral do Proad de hoje, dia 04/02/2013.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

1. Teri S Krebs
   1. Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
2. 
   
   Pål Ørjan Johansen pal.johansen@ntnu.no
   2. Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. 

Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. 

We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I² = 0%). Secondary outcomes, risk of bias and limitations are discussed. 

A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.